Skip to content
Screener

R&D at other companies

Eli Lilly logo
Eli LillyLLY
$3.82B+14.5%
LQD
Liquidia CorporationLQDA
$12.57M+80.5%
Lexicon Pharmaceuticals logo
Lexicon PharmaceuticalsLXRX
$17.44M+10.8%
Omada Health logo
Omada HealthOMDA
$14.63M+45.9%
Mineralys Therapeutics, Inc. logo
Mineralys Therapeutics, Inc.MLYS
$24.37M-35.7%
Viking Therapeutics logo
Viking TherapeuticsVKTX
$150.15M+263%

Segments

By segment

See full
All Other Segments$18M+31.6%

Other financials

Income statement

See full
Revenue$109.4M+42.9%
Gross profit$95.0M+32.0%
Operating income-$350.0K-107%
Net income-$19.0M-2,949%
EPS (diluted)-$0.06

Balance sheet

See full
Cash & equivalents$52.9M-7.2%
Total debt$11.8M-7.5%
Total equity-$67.2M-22.1%
Total assets$732.3M+77.9%

Cash flow

See full
Operating cash flow-$18.4M-305%
CapEx$5.1M+355%
Free cash flow-$23.5M-399%

Valuation

See full
Market cap$1.32B+25.9%
Enterprise value$1.28B+27.4%
P/S3.4×-0.1×

Profitability

See full
Gross margin89.8%-4.8pp
Operating margin23.3%+3.1pp
Net margin9.3%
FCF margin13.8%

Returns & leverage

See full
Return on equity44.2%
Debt / equity-0.2×
Current ratio1.7×-0.8×

Where this comes from

Reported directly by Mannkind in its filing.

Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost.

The source filing: Mannkind’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 4:07 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-335054
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Expenses:
Cost of goods sold – commercial, excluding amortization of acquired intangible assets14,4094,60721,9178,375
Cost of revenue – collaborations and services15,13115,96125,09429,709
Research and development18,00113,67535,23224,697
Selling, general and administrative58,30231,622112,38956,636
Amortization of acquired intangible assets4,3678,734
(Gain) loss on foreign currency transaction(486)5,363(1,804)7,872
Total expenses109,72471,228201,562127,289

ITEM 1. FINANCIAL STATEMENTS

FAQ

What is Mannkind's R&D?
Mannkind (MNKD) reported R&D of $18M in Q2 2026.
How has Mannkind's R&D changed year-over-year?
Mannkind's R&D increased by 31.6% year-over-year, from $13.68M to $18M.
What is the long-term trend for Mannkind's R&D?
Over 4 years (2021 to 2025), Mannkind's R&D has grown at a 52.4% compound annual growth rate (CAGR), from $12.31M to $66.35M.
What does R&D mean?
Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.

Ask your AI about Mannkind's r&d.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude